Skyepharma PLC Announces Regulatory Application

LONDON--(Marketwire - March 23, 2009) -

 SkyePharma Announces Filing of New Drug Application for FlutiformTM to the FDA LONDON, UK, 23 March 2009 -- SkyePharma PLC (“SkyePharma” or the"Company”) (LSE: SKP) today announces the filing of a New Drug Application (“NDA”) for FlutiformTM (fluticasone propionate/formoterol fumarate), SkyePharma’s lead development product for the maintenance treatment of asthma in patients 12 years of age and older, with the U.S. Food and Drug Administration. Primary endpoints were met in all of the clinical programmes required for the submission of the NDA, comprising a long-term safety study and four efficacy studies, covering nearly 2,300 patients. FlutiformTM HFA-MDI is a fixed-dose combination of an inhaled corticosteroid (ICS) fluticasone and formoterol, long-acting beta agonist (LABA) in a metered dose inhaler. ICS/LABA combinations are the fastest growing segment of the global asthma/COPD market, which was worth an estimated U.S. USD28.8 billion in 2007 globally. Dr. Ken Cunningham, CEO of SkyePharma said, “The submission of the NDA for FlutiformTM is a major milestone for SkyePharma. We believe that FlutiformTM, when approved, will provide physicians and asthma patients with an additional treatment option to better manage this serious, chronic condition.” SkyePharma will announce its results for the year ended 31 December 2008 on 26th March 2009. For further information please contact: SkyePharma PLC Ken Cunningham +44 20 7491 1777 Peter Grant Financial Dynamics David Yates +44 20 7831 3113 Jonathan Birt About SkyePharma PLC Using its proprietary drug delivery technologies, SkyePharma develops new formulations of existing products to provide a clinical advantage and life-cycle extension. The Company has twelve approved products in the areas of oral, inhalation and topical delivery. The Group’s products are marketed throughout the world by leading pharmaceutical companies. For more information, visit www.skyepharma.com. About FlutiformTM FlutiformTM HFA-MDI is a fixed-dose combination of fluticasone and formoterol in a metered dose inhaler (“MDI”). The product incorporates the most commonly prescribed inhaled anti-inflammatory corticosteroid (fluticasone propionate) and a fast onset long-acting beta-agonist (formoterol fumarate) in combination with an environmentally-friendly aerosol propellant hydrofluoroalkane (“HFA”) and is being developed for asthma. FlutiformTM is licensed in the U.S. to Abbott Respiratory LLC (formerly known as Kos Life Sciences, Inc.), a wholly owned subsidiary of Abbott. This information is provided by RNS The company news service from the London Stock Exchange END